Prompt action by Alabama rheumatologists has caused Blue Cross Blue Shield to rethink a policy denying all claims for injections into knees with osteoarthritis. But a similar "ban" on hyaluronic acid in neighboring Florida takes effect today.
A major disconnect in psoriatic arthritis treatment: Assessment tools and guidelines largely ignore flares. But over half of patients in two new surveys report severe flares or completely unremitting disease. Both are linked to poor outcomes.
A second biomarker panel shows promise in distinguishing osteoarthritis from rheumatoid arthritis early enough to prevent joint damage. This one relies partly on lack of antibody response to citrullinated proteins in early osteoarthritis.